Study details
Enrolling now
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
NCT IDNCT05093335ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
30
Study length
about 5.1 years
Ages
18+
Locations
1 site in NY
What this study is about
Researchers are testing a treatment called [68Ga]-Pentixafor to see how well it shows up in the body using PET/CT scans. The trial will involve people with conditions like Erdheim-Chester Disease, Histiocytic Neoplasms, Lymphoma, Multiple Myeloma, and Rosai-Dorfman Disease.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [68Ga]-Pentixafor
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Tumor standard uptake value (SUV)
Body systems
Oncology